靶向基因导向酶前药疗法应对晚期前列腺癌的多样性和侵袭性。

Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.

作者信息

Khatri Aparajita, Russell Pamela J

机构信息

Oncology Research Centre, Prince of Wales Hospital, Level 2, Clinical Sciences Building, Barker St., Randwick, NSW 2031, Australia.

出版信息

Discov Med. 2007 Feb;7(37):39-45.

PMID:17343804

Abstract

Late stage hormone refractory prostate cancer (HRPC) is presently incurable. Novel alternatives such as cytoreductive Gene Directed Enzyme Prodrug Therapy (GDEPT) offer great hope: The potential for in situ amplification of cytotoxicity due to GDEPT-associated "bystander effects" has special appeal for patients with prostate cancer, the prostate being dispensable. In this overview, recent developments in various GDEPT systems for treating prostate cancer are described. Research related to the enhancement of in situ GDEPT delivery and prostate cancer-targeting of viral vectors, is reviewed. The scope and progress of synergies between GDEPT and other treatment modalities, traditional and alternate, are discussed.

摘要

晚期激素难治性前列腺癌（HRPC）目前无法治愈。诸如细胞减灭性基因导向酶前药疗法（GDEPT）等新方法带来了巨大希望：由于GDEPT相关的“旁观者效应”，细胞毒性在原位放大的潜力对前列腺癌患者具有特殊吸引力，因为前列腺并非不可或缺。在本综述中，描述了用于治疗前列腺癌的各种GDEPT系统的最新进展。对与增强原位GDEPT递送以及病毒载体的前列腺癌靶向性相关的研究进行了综述。讨论了GDEPT与传统及其他治疗方式之间协同作用的范围和进展。